William Young

William Young has served as a member of our board of directors since December 2016. Mr. Young is a Senior Advisor with Blackstone Life Sciences. Prior to its acquisition by Blackstone, Mr. Young joined Clarus in March 2010 and held various roles, including Venture Partner, Senior Advisor and portfolio company board member. Prior to joining Clarus, Mr. Young was chairman of the board of directors and Chief Executive Officer of Monogram Biosciences from 2000 until its acquisition by Laboratory Corporation of America Holdings (NYSE: LH) in 2009.  Previously, Mr. Young spent 20 years at Genentech in roles of increasing responsibility, culminating as Chief Operating Officer from 1997 to 1999.  Mr. Young currently serves as a member of the board of directors of Theravance BioPharma Inc. (NASDAQ: TBPH) and Autolus Therapeutics plc (NASDAQ: AUTL). Mr. Young also served as the chairman of the board of directors of NanoString Technologies (NASDAQ: NSTG) from February 2010 to July 2024, and Annexon, Inc. (NASDAQ: ANNX) from March 2017 to February 2021, and as a member of the boards of directors of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) from May 2015 to June 2020 and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from September 2010 to November 2015. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology. Mr. Young received a B.S. in Chemical Engineering from Purdue University and an M.B.A. from Indiana University in Marketing and Finance and holds an honorary doctorate in Engineering from Purdue University.